A 40-week trial shows that Tirzepatide works better than Semaglutide for managing Type 2 diabetes

Published in NEJM on August 5, 2021.

In a groundbreaking study published in the New England Journal of Medicine on August 5, 2021, Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, and semaglutide, a selective GLP-1 receptor agonist, were compared in terms of how well they treat type 2 diabetes and how safe they are to use.